Skip to main content
Contact Us
Subscribe
E-Edition
81°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Curevac N.V.
(NQ:
CVAC
)
2.960
-0.040 (-1.33%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 3, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Curevac N.V.
< Previous
1
2
3
Next >
CureVac Announces Financial Results for the First Quarter of 2023 and Provides Business Update
May 30, 2023
Via
ACCESSWIRE
CureVac Announces Developments in Patent Litigation with Pfizer/BioNTech
May 19, 2023
Via
ACCESSWIRE
CureVac Announces Dosing of First Participant in Combined Phase 1/2 Study of Multivalent, Modified Influenza Vaccine Candidates Developed in Collaboration with GSK
May 08, 2023
Via
ACCESSWIRE
CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2022 and Provides Business Update
April 25, 2023
Via
ACCESSWIRE
CureVac to Report Fourth Quarter and Full-Year 2022 Financial Results and Business Updates on April 25, 2023
April 18, 2023
Via
ACCESSWIRE
CureVac Announces Voting Results of Extraordinary General Meeting
March 28, 2023
Via
ACCESSWIRE
CureVac Announces Closing of $250 million Follow-on Public Offering of Common Shares
February 10, 2023
Via
ACCESSWIRE
CureVac Announces Proposed Public Offering of Common Shares
February 07, 2023
Via
ACCESSWIRE
CureVac Welcomes Myriam Mendila as New Chief Development Officer
February 01, 2023
Via
ACCESSWIRE
CureVac Named as One of the World’s Most Dynamic Innovators by LexisNexis(R)
January 31, 2023
Via
ACCESSWIRE
CureVac Announces Positive Data in Older Adults from COVID-19 and Flu mRNA Vaccine Development Programs
January 30, 2023
Via
ACCESSWIRE
CureVac Appoints Alexander Zehnder as CEO From April 1, 2023
January 09, 2023
Via
ACCESSWIRE
CureVac Announces Positive Data on Joint COVID-19 and Flu mRNA Vaccine Development Programs
January 06, 2023
Via
ACCESSWIRE
CureVac Members of Management Sell Shares to Cover Tax Obligations from Long Term Incentive Program
December 14, 2022
Via
ACCESSWIRE
CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2022 and Provides Business Update
November 16, 2022
Via
ACCESSWIRE
CureVac Presents Preliminary Data from Phase 1 Study Expansion of Oncology Candidate CV8102
November 11, 2022
Via
ACCESSWIRE
CureVac to Report Third Quarter and First Nine Months 2022 Financial Results and Business Updates on November 16, 2022
November 10, 2022
Via
ACCESSWIRE
CureVac Announces Financial Results for the Second Quarter and First Half of 2022 and Provides Business Update
August 18, 2022
Via
ACCESSWIRE
CureVac Starts Phase 1 Clinical Study of Modified, Omicron-Targeting COVID-19 Vaccine Candidate
August 18, 2022
Via
ACCESSWIRE
CureVac Files Patent Infringement Lawsuit in Germany Against BioNTech
July 05, 2022
TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / July 5, 2022 / CureVac N.V. (NASDAQ:CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger...
From
CureVac
Via
AccessWire
Topics
Intellectual Property
Lawsuit
Exposures
COVID-19
Financial
Intellectual Property
CureVac Announces Voting Results of General Meeting
June 22, 2022
TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / June 22, 2022 / CureVac N.V. (Nasdaq:CVAC), a global clinical-stage biopharmaceutical company developing a new class of transformative medicines based on...
From
CureVac
Via
AccessWire
Exposures
COVID-19
CureVac Accelerates Oncology Strategy with Acquisition of Frame Cancer Therapeutics, Adding Novel Antigen Discovery Platform
June 08, 2022
TÜBINGEN, GERMANY and AMSTERDAM, NETHERLANDS / ACCESSWIRE / June 8, 2022 / CureVac N.V. (NASDAQ:CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on...
From
CureVac
Via
AccessWire
CureVac Announces Changes of CDO - Myriam Mendila to Succeed Klaus Edvardsen
June 08, 2022
TÜBINGEN, DEUTSCHLAND and BOSTON, MA / ACCESSWIRE / June 8, 2022 / CureVac N.V. (NASDAQ:CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger...
From
CureVac
Via
AccessWire
CureVac Partners with myNEO to Identify Novel Antigen Targets for mRNA-Based Cancer Vaccine Development
May 25, 2022
TÜBINGEN, GERMANY and GHENT, BELGIUM / ACCESSWIRE / May 25, 2022 / CureVac N.V. (Nasdaq:CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger...
From
CureVac
Via
AccessWire
Curevac Announces Financial Results For The First Quarter Of 2022 And Provides Business Update
May 25, 2022
TÜBINGEN, GERMANY and BOSTON MA / ACCESSWIRE / May 25, 2022 / CureVac N.V. (Nasdaq:CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger...
From
CureVac
Via
AccessWire
Exposures
COVID-19
CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2021 and Provides Business Update
April 28, 2022
Our newswire features a comprehensive, flat-fee Press Release service. Generate quality engagement with real-time analytics to improve visibility and expand your influence.
From
CureVac
Via
AccessWire
Exposures
COVID-19
CureVac to Report Fourth Quarter and Full-Year 2021 Financial Results and Business Updates on April 28, 2022
April 22, 2022
TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / April 22, 2022 / CureVac N.V. (NASDAQ:CVAC), a biopharmaceutical company developing a new class of transformative medicines based on messenger...
From
CureVac
Via
AccessWire
CureVac and GSK's Bivalent Second-Generation mRNA Vaccine Candidate Shown to be Highly Effective Against SARS-CoV-2 Variants in Preclinical Study
April 21, 2022
- Vaccine candidate combining Beta- and Delta-specific mRNAs shows strong protection and immune responses during preclinical challenge study - Demonstrated neutralizing capacity against the Omicron...
From
CureVac
Via
AccessWire
Exposures
COVID-19
CureVac and GSK Enter into Pandemic Preparedness Contract with German Government
April 11, 2022
- German government reserves domestic manufacturing capacity until 2029 to ensure rapid access to mRNA vaccines developed by CureVac and GSK - Five-year contract enables production of up to 80 million...
From
CureVac
Via
AccessWire
CureVac and GSK Start Clinical Development of Second-Generation COVID-19 Vaccine Candidate, CV2CoV
March 30, 2022
- Phase 1 dose-escalation study started at clinical sites in the U.S. - Milestone demonstrates CureVac's and GSK's continued execution on comprehensive clinical program of second-generation vaccine...
From
CureVac
Via
AccessWire
Exposures
COVID-19
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.